Assessment of MUcociLiary Transport timE in CRSwNP Patients in Treatment With Dupilumab: AMULET Study Authors: Alessia Giorli, Fabio Ferretti, Antonio Romano, Marco Casiraghi, Mariella Scarano, Paolo Farneti, Giacomo Sollini, Marco Mandalà, Ernesto Pasquini, Cesare Biagini Published: 2026 Introduction Chronic rhinosinusitis with nasal polyps with type 2 inflammation presents IL‐4 and IL‐13 as key drivers [1]. IL‐13 predominantly mediates mucus hypersecretion, disrupts ciliated cell differentiation, impairs epithelial barrier integrity, and compromises mucociliary clearance [2]. Patients with CRSwNP demonstrated markedly prolonged mucociliary transport time (MCTt), resulting in mucus hyperviscosity and rhinorrhea [3]. Dupilumab, a monoclonal antibody inhibiting IL‐4/IL‐13 signaling, has demonstrated efficacy in improving endoscopic and subjective outcomes [4]. However, its effects on mucociliary clearance have not been previously investigated. Our study examines how dupilumab treatment restores MCTt and enhances nasal mucosal barrier efficiency. Amid growing attention on nasal epithelium and its remodeling [5], MCTt measurements may serve as a relevant parameter for evaluating sinonasal inflammation and its modification with targeted therapies. Key Points Mucociliary transport time (MCTt), known to be impaired in CRSwNP, rapidly restores during dupilumab therapyIL‐13 inhibition enhances mucus rheology and ciliary motility, contributing to epithelial homeostasisMCTt may hold predictive value for clinical remission in CRSwNP patients receiving dupilumab Mucociliary transport time (MCTt), known to be impaired in CRSwNP, rapidly restores during dupilumab therapy Mucociliary transport time (MCTt), known to be impaired in CRSwNP, rapidly restores during dupilumab therapy IL‐13 inhibition enhances mucus rheology and ciliary motility, contributing to epithelial homeostasis IL‐13 inhibition enhances mucus rheology and ciliary motility, contributing to epithelial homeostasis MCTt may hold predictive value for clinical remission in CRSwNP patients receiving dupilumab MCTt may hold predictive value for clinical remission in CRSwNP patients receiving dupilumab Methods This observational prospective cohort study enrolled 40 adults with severe Type‐2 CRSwNP meeting Italian prescribing criteria for dupilumab. The study adhered to the Declaration of Helsinki and was approved by the Ethical Committee CEAVSE (Prot. no. 24066); all participants provided written informed consent. Patients were evaluated at baseline (T0) and at 1, 3, 6, 9, and 12 months (T1–T5). Our primary outcome was the assessment of MCTt, performed by applying charcoal powder as an inert tracer to the head of the inferior turbinate under endoscopic (or rhinoscopic) anterior control. Normal values are 13 ± 2 min, and longer time is considered pathological; when longer than 30 min, MCTt is considered blocked [3]. Transit time to the oropharynx was recorded to evaluate mucociliary clearance efficiency. Secondary endpoints included assessment of Nasal Polyp Score (NPS), modified Lund–Kennedy score (MLK), SNOT‐22, Sniffin’ Sticks identification test (SSIT), nasal cytology, and blood eosinophil count (BEC). Longitudinal changes across the six time points were analyzed using Friedman's test for repeated measures, using SPSS‐IBM 27.0 and MedCalc. Results The study included 40 patients (mean age 55.26±12.32 years; 16/40—40%—were female). In our sample, 38 patients (95%) had previously undergone at least one endoscopic sinus surgery, with a mean of 8.5±6.09 years from last procedure, ranging from 1 to 22. Asthma and ASA‐intolerance were reported respectively in 22/40 (55%) in 18/40 (45%) patients. All patients self‐reported a good adherence to INCS, and received dupilumab indication for CRSwNP—300 mg every 2 weeks with subcutaneous injection. Our results show that MCTt is significantly modified by dupilumab therapy in CRSwNP patients. At baseline (T0), mean MCTt was significantly prolonged (28.53±3.45 min). Following dupilumab initiation, MCTt showed a rapid and significant decrease at T1 (16.60±5.18 min; p < 0.0001). MCTt continued to decrease subsequently, with normalization of mean values at T2 (13.35±3.09 min). At T3, T4, and T5, a progressive slight decrease in MCTt was recorded with mean values of 12.13±1.8, 11.63±1.5, and 11.05±1.09, respectively, statistically significant compared to the baseline (p < 0.0001) (Figure 1). No increase over time was observed, with normalization thus remaining stable once achieved individually. At T5, MCTt values were normalized in all patients, and this aligns with the evidence that patients were all excellent/good responders at 12 months. Late normalization at T5 was observed only in one patient, classifiable as a “late” responder for other parameters as well, with a good response detectable at 12 months but not at 6 months (Table 1). MCTt modifications at different time points of the AMULET study. Patients were enrolled according to Italian prescribing criteria, and EPOS2020 guidelines, and further updates. Patients were evaluated at baseline (T0) before starting dupilumab therapy and underwent clinical follow‐ups after 1 (T1), 3 (T2), 6 (T3), 9 (T4), and 12 months (T5). Statistical analysis was performed with non‐parametric tests. To analyze MCTt at different time points, a Friedman's test for repeated measures was used to describe the significance of MCTt changes across the six time points. ****p < 0.0001; ***p < 0.001; **p < 0.01. TABLE 1Mucociliary transport time (MCTt) in our study population at different times since the starting of dupilumab therapy (no. of patients/40). The method expresses the ability of nasal respiratory epithelium mucociliary system to remove in an appropriate time all possible noxa that come into contact with the nasal mucosa. Charcoal powder is applied and endoscopic (or rhinoscopic) anterior control is performed; using nasal endoscopy, ongoing mucociliary clearance can be detected; time is measured when charcoal reaches the oropharynx. The test is not affected by the position of the head. We divided patients in three categories according to the state of mucociliary clearance: normal (13 ± 2 min), pathological (>15 min), or blocked (>30 min), with positive results already seen after 1 month in 52.5% of patients. All patients achieved normal MCTt at T5. T0: Baseline, T1: after 1 month, T2: after 3 months, T3: after 6 months, T4: after 9 months, and T5: after 12 months.T0 (%)T1 (%)T2 (%)T3 (%)T4 (%)T5 (%)Normal0 (0)21 (52.5)32 (80)38 (95)39 (97.5)40 (100)Pathological7 (17.5)17 (42.5)18 (20)2 (5)1 (2.5)0 (0)Blocked33 (82.5)2 (5%)0 (0)0 (0)0 (0)0 (0)Mean values (SD)28.53 (3.45)16.6 (5.18)13.35 (3.09)12.13 (1.8)11.63 (1.5)11.05 (1.09)John Wiley & Sons, Ltd. Mucociliary transport time (MCTt) in our study population at different times since the starting of dupilumab therapy (no. of patients/40). The method expresses the ability of nasal respiratory epithelium mucociliary system to remove in an appropriate time all possible noxa that come into contact with the nasal mucosa. Charcoal powder is applied and endoscopic (or rhinoscopic) anterior control is performed; using nasal endoscopy, ongoing mucociliary clearance can be detected; time is measured when charcoal reaches the oropharynx. The test is not affected by the position of the head. We divided patients in three categories according to the state of mucociliary clearance: normal (13 ± 2 min), pathological (>15 min), or blocked (>30 min), with positive results already seen after 1 month in 52.5% of patients. All patients achieved normal MCTt at T5. T0: Baseline, T1: after 1 month, T2: after 3 months, T3: after 6 months, T4: after 9 months, and T5: after 12 months. Significant improvements were observed across all secondary endpoints from T0 to T5 (p < 0.0001). NPS decreased from 5.50±1.26 to 0.98±1.44, while MLK “polyps”, “edema,” and “discharge” (bilateral range for each item: 0–4) dropped respectively from 3.95±0.32, 4, and 4 to 0.98±1.44, 0.33±0.66, and 0.25±0.67. SNOT‐22 decreased from 52.82±14.96 to 10.16±9.9, and SSIT rose from 3.64±3.77 to 11.31±2.08. Correlation analysis between MCTt and standard clinical parameters will be the subject of future publications. BEC was not significantly modified, with mean values of 0.43 ± 0.2 at T0 and 0.38 ± 0.38 at T5, respectively. No serious adverse events were recorded. Discussion Our results demonstrate that dupilumab significantly improves MCTt in severe CRSwNP patients, marking a critical investigation into functional mucosal recovery under biological therapy. The rapid modification of MCTt (Table 1) during dupilumab therapy may be attributable to direct inhibition of IL‐4 and primarily IL‐13, counteracting their pathological effects on mucus rheology and ciliary motility [6, 7]. The crucial role of these cytokines on ciliated and goblet cells could explain the restoration of normal mucociliary clearance when their activity is inhibited [8]. The recovery of MCTt may serve as an objective functional marker of mucosal remodeling during biological therapies [9]. Unlike symptom scores or NPS, MCTt provides a direct, measurable assessment of the recovery of mucociliary clearance, which represents a physiological mechanism and relates to sinonasal epithelium barrier integrity. Clinically, the normalization of MCTt in the entire cohort by 12 months underscores the significant impact of dupilumab on sinonasal mucosa recovery, giving new insight into the modifications of other clinical parameters. MCTt may also be useful for better describing a key parameter in the definition, diagnosis, and clinical management of CRSwNP, but otherwise undescribed, such as rhinorrhea. MCTt improvement correlation to other parameters’ modifications to support its role will be further published. In conclusion, our study demonstrates the efficacy of dupilumab in recovering the nasal epithelial barrier and restoring homeostasis, as evidenced by the significant improvement in MCTt, a correlation that had not been thoroughly explored before, to our knowledge. These findings highlight the importance of assessing functional parameters to capture the direct remodeling effects of biological therapies. MCTt assessment is an easy, repeatable, and noninvasive tool that should be considered for monitoring therapeutic response and defining remission in CRSwNP [10]. Future research could investigate the long‐term predictive value of MCTt for clinical control and remission in CRSwNP patients receiving dupilumab. Author Contributions Alessia Giorli: conceptualization, methodology, data collection, writing – original draft preparation, writing – review and editing. Fabio Ferretti: statistical analysis. Antonio Romano: conceptualization, data collection. Marco Casiraghi: data collection. Mariella Scarano: data collection. Giacomo Sollini: data collection. Paolo Farneti: methodology. Marco Mandalà: supervision. Ernesto Pasquini: data collection, writing – review and editing, supervision. Cesare Biagini: conceptualization, methodology, data collection, writing – review and editing, supervision. Funding This research received funding from Sanofi Regeneron as ISS (Prot. SGZ‐2022‐13785). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflicts of Interest A.G., A.R., C.B.: Lecture fees and participation in experts’ board meeting of Sanofi, GSK, Deca. P.F.: Lecture fees and participation in experts’ board meeting of GSK. M.S.: Lecture fees and participation in experts’ board meeting of Sanofi, GSK. All other authors declare no conflicts of interest.